These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24305610)

  • 1. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.
    Kim SC; Lee YS; Seo KK; Jung GW; Kim TH
    Int J Impot Res; 2014; 26(3):87-93. PubMed ID: 24305610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries.
    Mulhall JP; Hassan TA; Rienow J
    Int J Clin Pract; 2018 Apr; 72(4):e13074. PubMed ID: 29460994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
    Baydaroglu E; Eschwège P; Hubert J; El Osta R
    Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
    Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
    Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
    J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation.
    Carvalheira AA; Pereira NM; Maroco J; Forjaz V
    J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial.
    Conaglen HM; Conaglen JV
    J Sex Med; 2012 Mar; 9(3):857-65. PubMed ID: 22239731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care.
    Costa P; Grandmottet G; Mai HD; Droupy S
    J Sex Med; 2013 Jul; 10(7):1850-60. PubMed ID: 23679019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
    Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men.
    Lee DM; Nazroo J; Pendleton N
    Int J Impot Res; 2015 Jul; 27(4):146-51. PubMed ID: 25809698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.
    Travison TG; Hall SA; Fisher WA; Araujo AB; Rosen RC; McKinlay JB; Sand MS
    J Sex Med; 2011 Nov; 8(11):3051-7. PubMed ID: 21834873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
    Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
    J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.
    Rosenberg MT; Adams PL; McBride TA; Roberts JN; McCallum SW
    Int J Clin Pract; 2009 Jan; 63(1):27-34. PubMed ID: 19125990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
    Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
    Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
    Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
    J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study.
    Kitrey ND; Gruenwald I; Appel B; Shechter A; Massarwa O; Vardi Y
    J Urol; 2016 May; 195(5):1550-1555. PubMed ID: 26694904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of improved erectile function and rate of successful intercourse with improved emotional well-being assessed with the Self-Esteem And Relationship questionnaire in men treated with sildenafil for erectile dysfunction and stratified by age.
    Steidle CP; Stecher VJ; Pace C; Tseng LJ;
    Curr Med Res Opin; 2006 May; 22(5):939-48. PubMed ID: 16709315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicentre, randomised, double-blind, placebo-controlled trial.
    Heiman JR; Talley DR; Bailen JL; Oskin TA; Rosenberg SJ; Pace CR; Creanga DL; Bavendam T
    BJOG; 2007 Apr; 114(4):437-47. PubMed ID: 17284249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.